Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2016 (2016), Article ID 9605890, 11 pages
http://dx.doi.org/10.1155/2016/9605890
Research Article

Differential Roles of Peroxisome Proliferator-Activated Receptor-α and Receptor-γ on Renal Crystal Formation in Hyperoxaluric Rodents

1Department of Nephrourology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 4678601, Japan
2China-Japan Kidney Stone Research Center, Key Laboratory of Environment and Population Health of Liaoning Education Ministry, Shenyang Medical College, 146 Huanghe North Street, Shenyang 110034, China

Received 24 November 2015; Accepted 10 February 2016

Academic Editor: Markus P. Kummer

Copyright © 2016 Kazumi Taguchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Neisius and G. M. Preminger, “Stones in 2012: epidemiology, prevention and redefining therapeutic standards,” Nature Reviews Urology, vol. 10, no. 2, pp. 75–77, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. M. El-Zoghby, J. C. Lieske, R. N. Foley et al., “Urolithiasis and the risk of ESRD,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1409–1415, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Ando, T. Nagaya, S. Suzuki et al., “Kidney stone formation is positively associated with conventional risk factors for coronary heart disease in Japanese men,” The Journal of Urology, vol. 189, no. 4, pp. 1340–1346, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Kohjimoto, Y. Sasaki, M. Iguchi, N. Matsumura, T. Inagaki, and I. Hara, “Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan,” American Journal of Kidney Diseases, vol. 61, no. 6, pp. 923–929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. C. Lieske, “New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones,” Journal of the American Society of Nephrology, vol. 25, no. 2, pp. 211–212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Antonelli, N. M. Maalouf, M. S. Pearle, and Y. Lotan, “Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030,” European Urology, vol. 66, no. 4, pp. 724–729, 2014. View at Publisher · View at Google Scholar
  7. A. Okada, T. Yasui, S. Hamamoto et al., “Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity,” Journal of Bone and Mineral Research, vol. 24, no. 5, pp. 908–924, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. Khan, P. A. Glenton, and K. J. Byer, “Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline,” Kidney International, vol. 70, no. 5, pp. 914–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Joshi, W. Wang, A. B. Peck, and S. R. Khan, “Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys,” The Journal of Urology, vol. 193, no. 5, pp. 1684–1691, 2015. View at Publisher · View at Google Scholar
  10. K. Taguchi, A. Okada, H. Kitamura et al., “Colony-stimulating factor-1 signaling suppresses renal crystal formation,” Journal of the American Society of Nephrology, vol. 25, pp. 1680–1697, 2014. View at Google Scholar
  11. L. Zuo, K. Tozawa, A. Okada et al., “A paracrine mechanism involving renal tubular cells, adipocytes and macrophages promotes kidney stone formation in a simulated metabolic syndrome environment,” The Journal of Urology, vol. 191, no. 6, pp. 1906–1912, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Reel, M. Guzeloglu, A. Bagriyanik et al., “The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats,” Journal of Surgical Research, vol. 182, no. 1, pp. 176–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhou, X. Kong, P. Zhao et al., “Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury,” Kidney International, vol. 79, no. 12, pp. 1302–1311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Ruilope, M. Hanefeld, A. Lincoff et al., “Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a phase IIb, randomized study,” BMC Nephrology, vol. 15, article 180, 2014. View at Publisher · View at Google Scholar
  16. A. A. K. El-Sheikh and R. A. Rifaai, “Peroxisome proliferator activator receptor (PPAR)-γ ligand, but not PPAR-α, ameliorates cyclophosphamide-induced oxidative stress and inflammation in rat liver,” PPAR Research, vol. 2014, Article ID 626319, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Okada, S. Nomura, Y. Saeki et al., “Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney,” Journal of Bone and Mineral Research, vol. 23, no. 10, pp. 1629–1637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kadian, N. Mahadevan, and P. Balakumar, “Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 388–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. H.-C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L.-J. Ma, and A. B. Fogo, “The PPARγ agonist pioglitazone ameliorates aging-related progressive renal injury,” Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2380–2388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Pizzolato, “Histochemical recognition of calcium oxalate,” Journal of Histochemistry & Cytochemistry, vol. 12, pp. 333–336, 1964. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Li, K. K. Nagothu, V. Desai et al., “Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-α in mice confers protection during acute kidney injury,” Kidney International, vol. 76, no. 10, pp. 1049–1062, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Li and K. E. McMartin, “Strain differences in urinary factors that promote calcium oxalate crystal formation in the kidneys of ethylene glycol-treated rats,” The American Journal of Physiology—Renal Physiology, vol. 296, no. 5, pp. F1080–F1087, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Khan, “Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations,” The Journal of Urology, vol. 189, no. 3, pp. 803–811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Taguchi, A. Okada, S. Hamamoto et al., “Proinflammatory and metabolic changes facilitate renal crystal deposition in an obese mouse model of metabolic syndrome,” The Journal of Urology, vol. 194, no. 6, pp. 1787–1796, 2015. View at Publisher · View at Google Scholar
  25. Y. Fujii, A. Okada, T. Yasui et al., “Effect of adiponectin on kidney crystal formation in metabolic syndrome model mice via inhibition of inflammation and apoptosis,” PLoS ONE, vol. 8, no. 4, Article ID e61343, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Taguchi, A. Okada, T. Yasui et al., “Pioglitazone, a peroxisome proliferator activated receptor γ agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats,” Journal of Urology, vol. 188, no. 3, pp. 1002–1011, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. Frazier-Wood, J. M. Ordovas, R. J. Straka et al., “The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study,” Pharmacogenomics Journal, vol. 13, no. 4, pp. 312–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Kostapanos, M. Florentin, and M. S. Elisaf, “Fenofibrate and the kidney: an overview,” European Journal of Clinical Investigation, vol. 43, no. 5, pp. 522–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. L. Stoller, M. V. Meng, H. M. Abrahams, and J. P. Kane, “The primary stone event: a new hypothesis involving a vascular etiology,” Journal of Urology, vol. 171, no. 5, pp. 1920–1924, 2004. View at Publisher · View at Google Scholar · View at Scopus